Biomarin Pharmaceutical Company Leadership

Biomarin Pharmaceutical's latest congressional trading

Biomarin Pharmaceutical Management Team Effectiveness

The company has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 24th of April 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M. As of the 24th of April 2024, Net Income Applicable To Common Shares is likely to grow to about 170.9 M, while Common Stock Shares Outstanding is likely to drop about 127.6 M.

Biomarin Pharmaceutical Workforce Comparison

Biomarin Pharmaceutical Profit Margins

The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.

Biomarin Pharmaceutical Insider Trading History

Biomarin Pharmaceutical Notable Stakeholders

The success or failure of an entity such as Biomarin Pharmaceutical often depends on how effective the management is. Biomarin Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomarin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomarin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Biomarin Pharmaceutical's official financial statements usually reflect Biomarin Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Biomarin Pharmaceutical. For example, before you start analyzing numbers published by Biomarin accountants, it's critical to develop an understanding of what Biomarin Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.

Please note, the presentation of Biomarin Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomarin Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Biomarin Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biomarin Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of Biomarin Pharmaceutical's management manipulating its earnings.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.